Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?

Pavord, Sue; Scully, Marie; Lester, Will; Makris, Mike; Hunt, Beverley J

Pavord, Sue; Scully, Marie; Lester, Will; Makris, Mike; Hunt, Beverley J.

Pavord S; Department of Haematology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK. Electronic address: suepavord@doctors.org.uk.
Scully M; Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-NIHR UCLH/UC BRC, London, UK.
Lester W; Department of Haematology, University Hospitals Birmingham, Birmingham, UK.
Makris M; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Hunt BJ; Thrombosis & Haemophilia Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.

Lancet ; 398(10313): 1801, 2021 11 13.

Article in English | MEDLINE | ID: covidwho-1510435

Subject(s)

Vaccines; COVID-19 Vaccines; ChAdOx1 nCoV-19; Humans; Immunization, Secondary

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines Topics: Vaccines Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google